| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.05. | Lilly data point to 'maintenance' strategies for GLP-1 weight loss | ||
| 13.05. | Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B | ||
| 13.05. | [Podcast] Closing the Distance in Cancer Care | ||
| 12.05. | FDA chief Marty Makary resigns from agency, ending tumultuous tenure | ||
| 12.05. | Arvinas, Pfizer find new partner for 'Protac' breast cancer drug | ||
| 12.05. | Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion | ||
| 12.05. | A year after Vertex's big launch, pain drug research faces a pivotal moment | ||
| 11.05. | GSK cuts deal with Sino to broaden reach of hepatitis B drug | ||
| 11.05. | Inhibrx delivers 'differentiated' cancer drug data; Fractyl starts diabetes gene therapy trial | ||
| 11.05. | Biotech layoffs are easing, but is the worst over? | ||
| 11.05. | The capacity crunch in biopharma is a location problem | ||
| 11.05. | Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies | ||
| 08.05. | FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended | ||
| 08.05. | Lilly, Gilead lead pharma's M&A boom | ||
| 07.05. | Sarepta tumbles as its gene therapy sales decline further | ||
| 07.05. | Angelini to buy Catalyst in $4B play for rare neuro drugs | ||
| 07.05. | Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B | ||
| 07.05. | Entrada shares dive as Duchenne results disappoint | ||
| 06.05. | Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline | ||
| 06.05. | Novo hikes guidance on Wegovy pill's fast sales start | ||
| 06.05. | Avalo shares spike on skin drug data; BioNTech to cut staff | ||
| 06.05. | CellCentric raises $220M for a 'transformative' multiple myeloma medicine | ||
| 05.05. | Viridian data lift prospects for thyroid eye disease drug | ||
| 05.05. | Vertex earnings get muted investor response | ||
| 05.05. | Cytokinetics heart drug scores in closely watched trial |